{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:58:46Z","timestamp":1793642326962,"version":"4.5.1"},"reference-count":63,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,11,27]]},"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the benefits and harms of pregabalin in the management of neuropathic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Rapid review and meta-analysis of phase III, randomised, placebo-controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults aged 18 years and above with neuropathic pain defined according to the International Association for the Study of Pain criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Pregabalin or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Our primary outcomes were pain (as measured using validated scales) and adverse events. Our secondary outcomes were sleep disturbance, quality of life, Patient Global Impression of Change, Clinician Global Impression scale, anxiety and depression scores, overall discontinuations and discontinuations because of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 28 trials comprising 6087 participants. The neuropathic pain conditions studied were diabetic peripheral neuropathy, postherpetic neuralgia, herpes zoster, sciatica (radicular pain), poststroke pain and spinal cord injury-related pain. Patients who took pregabalin reported significant reductions in pain (numerical rating scale (NRS)) compared with placebo (standardised mean difference (SMD) \u22120.49 (95% CI \u22120.66 to \u22120.32, p&lt;0.00001), very low quality evidence). Pregabalin significantly reduced sleep interference scores (NRS) compared with placebo (SMD \u22120.38 (95% CI \u22120.50 to \u22120.26, p&lt;0.00001), moderate quality evidence. Pregabalin significantly increased the risk of adverse events compared with placebo (RR 1.33 (95% CI 1.23 to 1.44, p&lt;0.00001, low quality evidence)). The risks of experiencing weight gain, somnolence, dizziness, peripheral oedema, fatigue, visual disturbances, ataxia, non-peripheral oedema, vertigo and euphoria were significantly increased with pregabalin. Pregabalin was significantly more likely than placebo to lead to discontinuation of the drug because of adverse events (RR 1.91 (95% CI 1.54 to 2.37, p&lt;0.00001), low quality evidence).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pregabalin has beneficial effects on some symptoms of neuropathic pain. However, its use significantly increases the risk of a number of adverse events and discontinuation due to adverse events. The quality of the evidence from journal publications is low.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-023600","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T07:40:26Z","timestamp":1548142826000},"page":"e023600","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":122,"title":["Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0811","authenticated-orcid":false,"given":"Igho J","family":"Onakpoya","sequence":"first","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7008-8763","authenticated-orcid":false,"given":"Elizabeth T","family":"Thomas","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J","family":"Lee","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Goldacre","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-1992","authenticated-orcid":false,"given":"Carl J","family":"Heneghan","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences, Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"2025121422280015000_9.1.e023600.1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1570159X1201140117162802","article-title":"Pregabalin in neuropathic pain: evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr Neuropharmacol"},{"key":"2025121422280015000_9.1.e023600.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.09.008"},{"key":"2025121422280015000_9.1.e023600.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"2025121422280015000_9.1.e023600.4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6747"},{"key":"2025121422280015000_9.1.e023600.5","unstructured":"OpenPrescribing.net. High-level prescribing trends for Pregabalin (BNF code 0408010AE) across all GP practices in NHS England. 2010 https:\/\/openprescribing.net\/chemical\/0408010AE\/ (accessed 8th Mar 2018)."},{"key":"2025121422280015000_9.1.e023600.6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3892\/etm.2017.4102","article-title":"Morphine and pregabalin in the treatment of neuropathic pain","volume":"13","author":"Wang","year":"2017","journal-title":"Exp Ther Med"},{"key":"2025121422280015000_9.1.e023600.7","doi-asserted-by":"publisher","DOI":"10.1111\/add.13843"},{"key":"2025121422280015000_9.1.e023600.8","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2017.402"},{"key":"2025121422280015000_9.1.e023600.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4441"},{"key":"2025121422280015000_9.1.e023600.10","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-5-56"},{"key":"2025121422280015000_9.1.e023600.11","unstructured":"International Association for the Study of Pain. What is neuropathic pain? https:\/\/s3.amazonaws.com\/rdcms-iasp\/files\/production\/public\/AM\/Images\/GYAP\/What%20is%20Neuropathic%20Pain.pdf (accessed 19th Jan 2018)."},{"key":"2025121422280015000_9.1.e023600.12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4300\/JGME-D-11-00075.1","article-title":"A primer on the validity of assessment instruments","volume":"3","author":"Sullivan","year":"2011","journal-title":"J Grad Med Educ"},{"key":"2025121422280015000_9.1.e023600.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2025121422280015000_9.1.e023600.14","unstructured":"Review Manager (RevMan) (Computer program). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011."},{"key":"2025121422280015000_9.1.e023600.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.06.006"},{"key":"2025121422280015000_9.1.e023600.16","unstructured":"GRADEpro. Computer program on www.gradepro.org. Version 3.6: McMaster University, 2014."},{"key":"2025121422280015000_9.1.e023600.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2025121422280015000_9.1.e023600.18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-8-33"},{"key":"2025121422280015000_9.1.e023600.19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318281546b"},{"key":"2025121422280015000_9.1.e023600.20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"key":"2025121422280015000_9.1.e023600.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.032"},{"key":"2025121422280015000_9.1.e023600.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.02.007"},{"key":"2025121422280015000_9.1.e023600.23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/j.pain.0000000000000143","article-title":"Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial","volume":"156","author":"Holbech","year":"2015","journal-title":"Pain"},{"key":"2025121422280015000_9.1.e023600.24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/AJP.0000000000000445","article-title":"Efficacy and safety of once-daily controlled-release pregabalin for the treatment of patients with postherpetic neuralgia: a double-blind, enriched enrollment randomized withdrawal, placebo-controlled trial","volume":"33","author":"Huffman","year":"2017","journal-title":"Clin J Pain"},{"key":"2025121422280015000_9.1.e023600.25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5214\/ans.0972.7531.1118405","article-title":"A study on efficacy of Pregabalin in acute Herpetic Neuralgia","volume":"18","author":"Kanodia","year":"2011","journal-title":"Ann Neurosci"},{"key":"2025121422280015000_9.1.e023600.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.12.023"},{"key":"2025121422280015000_9.1.e023600.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-010-1345-x"},{"key":"2025121422280015000_9.1.e023600.28","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"key":"2025121422280015000_9.1.e023600.29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/papr.12413","article-title":"A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin for postherpetic neuralgia in a population of Chinese patients","volume":"17","author":"Liu","year":"2017","journal-title":"Pain Pract"},{"key":"2025121422280015000_9.1.e023600.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614292"},{"key":"2025121422280015000_9.1.e023600.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.01.014"},{"key":"2025121422280015000_9.1.e023600.32","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12014"},{"key":"2025121422280015000_9.1.e023600.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.12.007"},{"key":"2025121422280015000_9.1.e023600.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.05.001"},{"key":"2025121422280015000_9.1.e023600.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.01.001"},{"key":"2025121422280015000_9.1.e023600.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03152.x"},{"key":"2025121422280015000_9.1.e023600.37","first-page":"745","article-title":"Amitriptyline Vs Pregabalin in Painful Diabetic Neuropathy A Randomised Placebo-Based Study","volume":"5","author":"Shabbir","year":"2011","journal-title":"P J M H S"},{"key":"2025121422280015000_9.1.e023600.38","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000244422.45278.ff"},{"key":"2025121422280015000_9.1.e023600.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ccc6ef"},{"key":"2025121422280015000_9.1.e023600.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.05.027"},{"key":"2025121422280015000_9.1.e023600.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.05.014"},{"key":"2025121422280015000_9.1.e023600.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2007.05.003"},{"key":"2025121422280015000_9.1.e023600.43","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80404"},{"key":"2025121422280015000_9.1.e023600.44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02979.x"},{"key":"2025121422280015000_9.1.e023600.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.06.033"},{"key":"2025121422280015000_9.1.e023600.46","doi-asserted-by":"publisher","DOI":"10.1111\/aas.12420"},{"key":"2025121422280015000_9.1.e023600.47","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009167","article-title":"The efficacy of pregabalin for acute pain control in herpetic neuralgia patients: A meta-analysis","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine"},{"key":"2025121422280015000_9.1.e023600.48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-11-85"},{"key":"2025121422280015000_9.1.e023600.49","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2105"},{"key":"2025121422280015000_9.1.e023600.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70251-0"},{"key":"2025121422280015000_9.1.e023600.51","first-page":"CD010567","article-title":"Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews","volume":"11","author":"Wiffen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121422280015000_9.1.e023600.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"2025121422280015000_9.1.e023600.53","doi-asserted-by":"publisher","DOI":"10.1111\/papr.12146"},{"key":"2025121422280015000_9.1.e023600.54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"2025121422280015000_9.1.e023600.55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182166ebe"},{"key":"2025121422280015000_9.1.e023600.56","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/754693"},{"key":"2025121422280015000_9.1.e023600.57","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/17512433.2016.1240029","article-title":"Methodological issues associated with clinical trials in neuropathic pain","volume":"9","author":"Gilron","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025121422280015000_9.1.e023600.58","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/jrsm.1255","article-title":"Comparison of a full systematic review versus rapid review approaches to assess a newborn screening test for tyrosinemia type 1","volume":"8","author":"Taylor-Phillips","year":"2017","journal-title":"Res Synth Methods"},{"key":"2025121422280015000_9.1.e023600.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.12.016"},{"key":"2025121422280015000_9.1.e023600.60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"2025121422280015000_9.1.e023600.61","doi-asserted-by":"crossref","first-page":"e28110","DOI":"10.5812\/aapm.28110","article-title":"Efficacy of Pregabalin in the Treatment of Radicular Pain: Results of a Controlled Trial","volume":"5","author":"Malik","year":"2015","journal-title":"Anesth Pain Med"},{"key":"2025121422280015000_9.1.e023600.62","unstructured":"NHS Gloucestershire. Guidance for Review of Patients taking Pregabalin for Neuropathic Pain. Available at http:\/\/www.gloshospitals.nhs.uk\/SharePoint19\/Chronic%20and%20Acute%20Pain%20Services%20Web%20Documents\/Pregabalin%20review%20(neuropathic%20pain)%20mg%204%20(2).pdf (Last accessed 1st Mar 2018)."},{"key":"2025121422280015000_9.1.e023600.63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-2197.2008.04730.x"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-023600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:28:16Z","timestamp":1765780096000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-023600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1,21]]},"published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1136\/bmjopen-2018-023600"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-023600","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}